USA - NASDAQ:CERT - US15687V1098 - Common Stock
The current stock price of CERT is 12.66 USD. In the past month the price increased by 7.29%. In the past year, price increased by 24.12%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 39.33 | 48.03B | ||
| DOCS | DOXIMITY INC-CLASS A | 44.86 | 12.52B | ||
| WAY | WAYSTAR HOLDING CORP | 35.11 | 7.44B | ||
| HTFL | HEARTFLOW INC | N/A | 3.16B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.67B | ||
| SDGR | SCHRODINGER INC | N/A | 1.66B | ||
| PHR | PHREESIA INC | N/A | 1.41B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 11.29 | 1.37B | ||
| CTEV | CLARITEV CORP | N/A | 1.15B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.07B | ||
| EVH | EVOLENT HEALTH INC - A | N/A | 917.75M | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | N/A | 909.88M |
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Radnor, Pennsylvania and currently employs 1,487 full-time employees. The company went IPO on 2020-12-11. The company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. The company delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. The company offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
CERTARA INC
4 Radnor Corporate Center, Suite 350
Radnor PENNSYLVANIA 08540 US
CEO: William F. Feehery
Employees: 1517
Phone: 14152378272
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Radnor, Pennsylvania and currently employs 1,487 full-time employees. The company went IPO on 2020-12-11. The company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. The company delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. The company offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
The current stock price of CERT is 12.66 USD. The price increased by 1.28% in the last trading session.
CERT does not pay a dividend.
CERT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
CERT stock is listed on the Nasdaq exchange.
CERTARA INC (CERT) operates in the Health Care sector and the Health Care Technology industry.
CERTARA INC (CERT) has a market capitalization of 2.03B USD. This makes CERT a Mid Cap stock.
ChartMill assigns a technical rating of 9 / 10 to CERT. When comparing the yearly performance of all stocks, CERT is one of the better performing stocks in the market, outperforming 80.28% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to CERT. Both the profitability and the financial health of CERT get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months CERT reported a non-GAAP Earnings per Share(EPS) of 0.49. The EPS increased by 32.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.97% | ||
| ROA | 0.52% | ||
| ROE | 0.75% | ||
| Debt/Equity | 0.27 |
18 analysts have analysed CERT and the average price target is 14.73 USD. This implies a price increase of 16.38% is expected in the next year compared to the current price of 12.66.
For the next year, analysts expect an EPS growth of -0.92% and a revenue growth 9.9% for CERT